Replies to post #219437 on Biotech Values

[jbog]

Enanta initiated with a Buy at Roth Capital Roth Capital analyst Yasmeen Rahimi started Enanta with a Buy rating and $133 price target, citing the company's two blockbuster HCV drugs, Viekira and Mavyret, and a third major blockbuster likely from RSV.

Read more at:
https://thefly.com/landingPageNews.php?id=2741373

[DewDiligence]

Musings on ENTA's recent strength:

https://twitter.com/DewDiligence/status/1016121378762784769